would buyer ci share detail analyst day reinforc belief
segment grow y/i acceler growth along
ci long-term growth expect segment stronger expect give
us greater confid abil hit target ep ep
find share attract
suspect core adj oper incom slightli y/i
believ y/i declin could attribut impact new health plan
client implement take time ramp run-rate profit invest
spend associ merger chang account method stock
comp profit ramp remaind year
analysi suggest profit could y/i full year profit
grow modestli
compani growth strategi focus primarili gain share within select
middl market segment maintain share nation account grow medicar
advantag compani expect annual growth medicar advantag
begin earli quantifi potenti revenu
synergi deal cross-sel product servic compani client
base key growth driver
ci target commerci medic cost trend approxim line annual consum
price cpi growth rang combin esrx key
driver enabl better integr medic pharmaci benefit particular
emphasi manag specialti spend
growth primarili driven leverag express script
highli complimentari geograph footprint expand relationship within compani
respect client base specialti growth accredo express script
substanti market share mani geographi strong
presenc vice versa exampl compani highlight louisiana michigan
minnesota ohio pennsylvania washington state
highest market share similarli higher market share florida texa
express script strong presenc compani believ
strong cross-sel opportun leverag evicor accredo benefit
integr medic custom instanc pharmaci medic manag
solut current carv today deliv industry-lead
pharmaci cost trend commerci client neg medicar
compani bring compel valu proposit market especi larg
aso book benefit directli lower cost
accredo posit drive growth especi wave specialti gener
expect come market compani estim potenti opportun
next five year industri leader limit distribut drug accredo growth
acceler begin manag spend integr medic custom
pleas see page report import disclosur
posit share ci believ acquisit esrx posit compani
succeed evolv healthcar landscap stand-alon basi ci carv
strong posit market particularli aso recent result demonstr
abil deliv strong result led critic compani spend
billion acquir esrx reflect rel depress valuat compar peer
believ unwarr believ investor may give enough credit
near-term growth opportun yet outlin beyond million cost synergi
greater purchas scale esrx ci posit full-risk
aso market believ strateg valu esrx even potenti
near-term accret lie long-term posit market shift toward greater care
coordin value-bas care
oper earn grow y/i
grow y/i
stronger expect medic custom
realiz pre-tax cost synergi excess
integr challeng lower
expect synergi esrx deal
global health servic compani subsidiari offer medic dental
disabl life accid insur relat product servic
product servic offer employ group select
intern market offer supplement health life accid insur product
intern health care coverag servic busi government non-
government organ individu decemb acquir
script largest pharmaci benefit manag script servic includ
drug util review formulari manag diseas manag medic drug
data analysi servic medic inform manag servic oper five
segment integr medic intern market oper
corpor
compani provid initi adjust script guidanc approxim
line expect expect adj organ script growth
client retent note alreadi secur two new health plan win
expect billion adjust script includ organ growth
script insourc script expect gener annual
revenu indic lower revenu per adj script rel legacy-
express script roll back retail network busi estim
script transit onto express script platform
commerci growth driven share gain within compani exist footprint
focu select market segment expans number
go deeper market next year compani believ signific
room grow select market segment ci share
respect combin segment repres total commerci
employ market expand relationship client specialti solut growth
core element compani strategi made compel follow
combin express script believ better drug purchas econom
enabl ci price product competit gain share particularli select
segment compani offer bundl medical-pharmaci product number
new solut avail custom via combin express script line
ci consult approach offer client wide rang customiz product
medicar advantag primari growth driver govern segment ci
target compound-annual-growth-rate growth like toward lower end
rang earli year ramp outer year ci expect drive growth
geograph expans compani increas countri footprint
three new market entranc expans adjac counti four exist
market introduct new ppo product eight market expect compani
priorit market compani alreadi strong commerci presenc
order leverag portion exist infrastructur network particularli
provid collabor care arrang expans ppo product anoth
import compon ci growth plan compani histor particip
meaning hmo-typ product ci also expect gain share exist hmo
product portfolio like competit price enabl express script
combin final compani intend increas particip group
medicar advantag market believ like smaller compon ci growth
strategi compani indic seek leverag relationship commerci
client highli target basi
suspect core adj operta incom slightli y/i
believ y/i declin could attribut impact new health plan client
implement take time ramp run-rate profit invest spend
associ merger chang account method stock comp
convers compani suggest oper expens may higher y/
partial due chang legaci esrx account methodolog stock-bas
compens ci method result larger accrual
result y/i result aforement driver
believ investor look indic long-term health servic
perform look impli growth base guidanc would suggest
ebit around y/i ebit margin well think reflect item
purchas scale pharmaci layer particularli legaci mail-ord
initi benefit in-sourc pbm back offic function optum
manag given specif guidanc two item note
track
figur comparison pro-forma
figur comparison pro-forma
think addit clariti perform give investor
greater confid compani abil achiev long-term target
revis assumpt reflect stronger expect growth rate across
segment lower adj oper margin segment
insourc script pull forward share repurchas
updat oper cash flow guidanc result chang increas
adj ep estim decreas estim
adj ep estim line ci target price target
unchang impli share trade adj ep estim
believ stock attract valu share trade adj ep
continu believ market overli discount share ci manag care
peer due perceiv political/legisl threat creat headlin risk unlik
ever materi
million except per-shar data
cowen compani
invest cost benefit expens servic pharmaci oper non-control interest incom pre-tax adjust oper net non-control interest incom incom adjust oper share outstand fulli net incom reconcili net chang servic incom end decemb cowen
million except per-shar data
compani report cowen compani
invest cost benefit expens servic pharmaci oper non-control interest incom pre-tax adjust oper net non-control interest incom loss adjust incom adjust oper share outstand fulli net incom reconcili amort acquir intang realiz gain chang y/i invest cost benefit servic pre-tax incom cowen
million
compani report cowen compani
receiv current polici acquisit tax asset asset account insur contracthold servic cost expens insur contracthold tax liabil non-curr account non-controlling equitycommon paid comprehens treasuri stock sharehold liabil sharehold liquid ratio current receiv claim payabl structur long-term solvenc ratio return invest capit averag total asset averag stockhold equiti end decemb cowen
million
compani report cowen compani
invest gain incom extinguish chang asset liabil net non-oper effect account polici acquisit servic cost payabl accru expens oper net cash equip purchas invest repay debt common common foreign currenc rate chang cash cash increas decreas end decemb cowen
million
compani report cowen compani
invest gain loss incom tax benefit extinguish chang asset liabil net non-oper effect account polici acquisit servic cost payabl accru expens oper invest sold fix matur equiti matur repay fix matur equiti sale matur purchas fix matur equiti primarili short-term equip net cash invest interest credit contracthold deposit benefit payment contracthold deposit chang short-term debt long-term proce issuanc long-term common common financ foreign currenc rate chang cash cash increas decreas cowen
valu manag care stock use pe multipl forward earn manag care
sector trade averag forward year earn past year
peak trough troubl econom time
frame given reform-rel multi-year top-lin growth prospect believ sector
trade high end recent histor valuat
success individu public exchang remain consider question mark
head third year program final year two three premium
stabil program reinsur risk corridor although exchang profit
expect improv expect continu money lose enterpris
industri particip receipt risk corridor payment remain potenti threat
success compani reli receiv medicar advantag payment
reduct includ potenti introduct new risk adjust model could
reduc futur medicar advantag margin growth prospect rel expect
gener medicaid payment expans popul gener
howev mount evid state like reduc payment level
medic cost trend mute past year uptick underli
medic cost may difficult predict product price within commerci
integr esrx anoth potenti risk particularli compani eventu move
ci live onto esrx platform also begin march began transit
membership pbm ingeniorx support disrupt could
impact ci note esrx tsa run
transit work move would need negoti
potenti propos hh regard futur rebat could impact ci
would expect potenti impact headlin risk vs meaning impact
remain chanc administr could propos sweep broad new
